Familial adenomatous polyposis by Half, Elizabeth et al.
BioMed  Central
Page 1 of 23
(page number not for citation purposes)
Orphanet Journal of Rare Diseases
Open Access Review
Familial adenomatous polyposis
Elizabeth Half*1, Dani Bercovich2,3 and Paul Rozen4,5
Address: 1Familial Cancer Clinic, Gastroenterology Dept, Meir Hospital, Kfar Saba, Israel, 2Human Molecular Genetics & Pharmacogenetics, Migal 
- Galilee Bio-Technology Center, Kiryat-Shmona, 11016, Israel, 3Tel-Hai Academic College, Israel, 4Sestopali Fund for Gastrointestinal Cancer 
Prevention, Dept of Gastroenterology, Tel Aviv Medical Center, 6 Weizmann St, Tel Aviv, 64239, Israel and 5Tel Aviv University Medical School, 
Israel
Email: Elizabeth Half* - eohalf@yahoo.com; Dani Bercovich - danib@migal.org.il; Paul Rozen - prozen@012.net.il
* Corresponding author    
Abstract
Familial adenomatous polyposis (FAP) is characterized by the development of many tens to thousands of adenomas in the rectum
and colon during the second decade of life. FAP has an incidence at birth of about 1/8,300, it manifests equally in both sexes,
and accounts for less than 1% of colorectal cancer (CRC) cases. In the European Union, prevalence has been estimated at 1/
11,300-37,600. Most patients are asymptomatic for years until the adenomas are large and numerous, and cause rectal bleeding
or even anemia, or cancer develops. Generally, cancers start to develop a decade after the appearance of the polyps. Nonspecific
symptoms may include constipation or diarrhea, abdominal pain, palpable abdominal masses and weight loss. FAP may present
with some extraintestinal manifestations such as osteomas, dental abnormalities (unerupted teeth, congenital absence of one or
more teeth, supernumerary teeth, dentigerous cysts and odontomas), congenital hypertrophy of the retinal pigment epithelium
(CHRPE), desmoid tumors, and extracolonic cancers (thyroid, liver, bile ducts and central nervous system). A less aggressive
variant of FAP, attenuated FAP (AFAP), is characterized by fewer colorectal adenomatous polyps (usually 10 to 100), later age
of adenoma appearance and a lower cancer risk. Some lesions (skull and mandible osteomas, dental abnormalities, and fibromas
on the scalp, shoulders, arms and back) are indicative of the Gardner variant of FAP. Classic FAP is inherited in an autosomal
dominant manner and results from a germline mutation in the adenomatous polyposis (APC) gene. Most patients (~70%) have a
family history of colorectal polyps and cancer. In a subset of individuals, a MUTYH mutation causes a recessively inherited
polyposis condition, MUTYH-associated polyposis (MAP), which is characterized by a slightly increased risk of developing CRC
and polyps/adenomas in both the upper and lower gastrointestinal tract. Diagnosis is based on a suggestive family history, clinical
findings, and large bowel endoscopy or full colonoscopy. Whenever possible, the clinical diagnosis should be confirmed by
genetic testing. When the APC mutation in the family has been identified, genetic testing of all first-degree relatives should be
performed. Presymptomatic and prenatal (amniocentesis and chorionic villous sampling), and even preimplantation genetic
testing is possible. Referral to a geneticist or genetic counselor is mandatory. Differential diagnoses include other disorders
causing multiple polyps (such as Peutz-Jeghers syndrome, familial juvenile polyps or hyperplastic polyposis, hereditary mixed
polyposis syndromes, and Lynch syndrome). Cancer prevention and maintaining a good quality of life are the main goals of
management and regular and systematic follow-up and supportive care should be offered to all patients. By the late teens or
early twenties, colorectal cancer prophylactic surgery is advocated. The recommended alternatives are total proctocolectomy
and ileoanal pouch or ileorectal anastomosis for AFAP. Duodenal cancer and desmoids are the two main causes of mortality
after total colectomy, they need to be identified early and treated. Upper endoscopy is necessary for surveillance to reduce the
risk of ampullary and duodenal cancer. Patients with progressive tumors and unresectable disease may respond or stabilize with
a combination of cytotoxic chemotherapy and surgery (when possible to perform). Adjunctive therapy with celecoxib has been
approved by the US Food and Drug Administration and the European Medicines Agency in patients with FAP. Individuals with
FAP carry a 100% risk of CRC; however, this risk is reduced significantly when patients enter a screening-treatment program.
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Disease names
Familial adenomatous polyposis (FAP)
Synonyms
Familial polyposis coli
Variants or FAP-associated conditions
Attenuated FAP is a milder form of FAP
Gardner's syndrome is a clinical variant of FAP where the
extra-colonic features are prominent
Turcot syndrome refers to FAP and having a medulloblas-
toma brain tumor
Definition
FAP is an autosomal dominant disease that is classically
characterized by the development of hundreds to thou-
sands of adenomas in the rectum and colon during the
second decade of life. Almost all patients will develop
colorectal cancer (CRC) if they are not identified and
treated at an early stage. However, today it is unusual for
patients to present with CRC as the majority of patients
are diagnosed before cancer develops.
Attenuated FAP is a milder form that is characterized by
fewer adenomas, a later age of adenoma development and
cancer diagnosis.
Epidemiology
Worldwide, CRC is a major cause of cancer associated
morbidity and mortality. Its incidence varies considerably
among different populations with the highest incidence
reported from Western and industrialized countries.
Worldwide, about 85% of CRCs are considered to be spo-
radic, while approximately 15% are familial with FAP
accounting for less than 1% (Fig. 1). However, FAP is one
of the best known and understood genetic diseases.
In many countries there are local FAP registries; however
it is difficult to obtain accurate nation-wide data. In the
UK, Reed and Neel presented a detailed genetic study in
1955 and calculated the incidence of FAP at birth to be
1:8,300 [1]. In 1975, Alm presented an incidence rate of
1:7,645 in Sweden [2]. These estimates were based on
clinical criteria before the availability of mutation analysis
and recognition of all the clinical variants and differential
diagnoses. In 2009, the European Medicines Agency
(EMEA) estimated that FAP affected approximately 3-10/
100,000 people in the European Union which is equiva-
lent to 11,300 - 37,600 individuals [3]. Clinically, FAP
manifests equally in both sexes by the late teens and in the
twenties age group.
Clinical description
Symptoms are uncommon in the child and adolescent
until the adenomas are large and numerous so as to cause
rectal bleeding or even anemia. Other non-specific com-
plaints such as change in bowel habits, constipation, or
diarrhea, abdominal pains or palpable abdominal masses
or weight loss in young patients can lead to recto-sigmoid
examination and identification of polyps suggestive of
FAP. FAP can present with extraintestinal manifestations
such as osteomas, dental abnormalities (unerupted teeth,
congenital absence of one or more teeth, supernumerary
teeth, dentigerous cysts, and odontomas), congenital
hypertrophy of the retinal pigment epithelium (CHRPE),
desmoid tumors, or extracolonic cancers (thyroid, liver,
bile ducts, central nervous system), (see below). Some
lesions (skull and mandible osteomas, dental abnormali-
ties, fibromas on the scalp, shoulders, arms, and back) are
indicative of the Gardner variant of FAP. Today the condi-
tion should rarely present as a colonic or even as an extra-
colonic malignancy.
Colonic manifestations
Classic FAP is characterized by the presence of hundreds
to thousands of colorectal adenomas of different sizes.
Today this is rarely seen in countries with well developed
public health services. In the majority of patients polyps
begin to develop during childhood, mostly in the distal
colon (rectosigmoid) as small intramucosal nodules (Fig.
2A). By the time of adolescence, the polyps are usually
identified throughout the colon and, thereafter, increase
in size and numbers (Fig. 2B). About half of FAP patients
Relative and approximate contributions of familial causes to  the incidence of colorectal cancer Figure 1
Relative and approximate contributions of familial 
causes to the incidence of colorectal cancer. FAP - 
Familial adenomatous polyposis, JP - Familial juvenile polypo-
sis, PJ - Peutz-Jeghers syndrome, HNPCC - Hereditary non-
polyposis colorectal cancer (Lynch Syndrome). Note the 
very small contribution of FAP to the etiology of cancer.Orphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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develop adenomas by 15 years of age and 95% by age 35
years [4].
Generally, cancers start to develop a decade after the
appearance of the polyps. So, if the colon is left intact, the
majority of patients with FAP eventually develop CRC by
the ages 40-50 years. However, it should be emphasized
that, although uncommon, CRC can develop in children
or in older adults.
Other gastrointestinal manifestations
Individuals with FAP can also develop a variety of extra-
colonic gastrointestinal manifestations (3A).
In the stomach, fundic gland polyps (FGP) develop in 90%
of patients with FAP. They are of special interest since, in
contrast to the benign nature of sporadic FGP, 40% of
these lesions in individuals with FAP have been shown to
have adenomatous features, but rarely do progress to can-
cer [5]. FGPs in FAP patients are pathogenetically distinct
from sporadic FGPs. Somatic, second-hit APC gene altera-
tions, which precede morphological dysplasia in many
FAP-associated FGPs, indicate that FGPs arising in the set-
ting of FAP are neoplastic lesions [6].
Adenomatous polyps in the duodenum (mainly in the 2nd and
3rd parts) and periampullary region. In one series they devel-
oped in approximately 90% of individuals with FAP, 10-
20 years after diagnosis of colorectal polyps [7]. The life-
time risk of duodenal adenomas has been reported to
reach 100% [8,9]. Spigelman's classification of duodenal
polyps is a scale, based on polyp number, size, histology,
and severity of dysplasia (Table 1). It is estimated that
about 5% of duodenal, and specifically periampulary pol-
yps, progress to cancer within 10 years [10]. While rare in
the general population, the risk of duodenal or periamp-
ullary cancer is increased several hundred fold in FAP
patients [7]. Duodenal polyposis usually progresses in an
orderly fashion through increasing Spigelman stage [7],
but cancer can present in patients under surveillance with
lower Spigelman stages being identified in their penulti-
mate examinations [10-12]. Pancreatitis can be the result
of ampullary adenoma or as a presentation of malig-
nancy.
Small bowel adenomas. It is well known that individuals
with FAP carry a risk of small bowel polyps and even can-
cer although at a much lower rate than duodenal and
ampulary neoplasms. The exact incidence of small bowel
polyps is unknown and is generally dependent on the
examining methodology used for evaluation. Bertoni G et
al., in 1993, studied 16 patients with FAP by push enter-
oscopy and detected jejunal polyps in 50% of subjects
[13]. Later, with the use of double balloon enteroscopy or
capsule endoscopy, the rate of jejunal and ileal polyps was
estimated to be between 30-75% [14-16]. The rate of
small bowel malignancy is much lower than ampullary or
duodenal cancer. However, the treating physician should
be aware of this possibility and be ready to implement
surveillance, which will be discussed.
Extra-intestinal manifestations
Extraintestinal manifestations of FAP, which are rarely
malignant, include: cutaneous lesions such as fibromas, lipo-
mas, sebaceous and  epidermoid cysts,  and nasopharyngeal
angiofibromas (Fig 4A). Osteomas can be palpated or seen,
they can be identified as occult radio-opaque jaw lesions,
and dental abnormalities which can be disfiguring (Fig.
4B). Gardner described the presence of these extraintesti-
nal lesions and this phenotypic variant is named after him
as "Gardner syndrome" [17]. Congenital hypertrophy of the
retinal pigment epithelium (CHRPE) is a patch(s) of discol-
oration in the ocular fundus but is not specific for FAP
(Fig. 4C). Almost all patients with CHRPE do not have
symptoms and the lesions are found during examination
of the dilated eye. However, when multiple bilateral
lesions occur it can be a sensitive phenotypic marker and
calls for screening. Low-grade adenocarcinoma has been
described in these lesions [18,19].
Individuals with FAP may develop soft-tissue tumors
(desmoid tumors) in the mesentery, abdominal wall or
areas of scars. These tumors are considered benign, but by
progressive enlargement and consequently pressure on
gastrointestinal or urinary tracts, local nervous or vascular
system, can be life threatening. Desmoids can be both a
cause of severe morbidity as well as mortality. Over a life-
time, desmoid tumors occur in approximately 8% of men
and 13% of women with FAP [20].
Panel A shows the endoscopic appearance of early FAP ade- nomas; panel B shows the endoscopic appearance of estab- lished, multiple, FAP adenomas Figure 2
Panel A shows the endoscopic appearance of early 
FAP adenomas; panel B shows the endoscopic 
appearance of established, multiple, FAP adenomas.
A BOrphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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Other extracolonic malignancies
Other extra-colonic malignancies that are associated with
FAP include pancreatic mucinous adenocarcinomas, liver
(hepatoblastoma), and brain tumors. In 1959, Turcot and
colleagues described two teenaged siblings with adenom-
atous polyps of the colorectum in whom malignant
tumors of the central nervous system developed [21].
Later it was noticed that "Turcot syndrome" is heterogene-
ous, encompassing at least two subtypes. The first is char-
acterized by a germline mutation in one of the DNA
mismatch repair genes, such as hPSM2  or hMLH1 and
presents with the occurrence of glioblastoma in patients
with Lynch syndrome (hereditary non-polyposis colon
cancer, HNPCC). A second Turcot subtype is characterized
by medulloblastoma, or rarely glioblastoma, in the setting
Panel A illustrates the extracolonic upper gastrointestinal polyp manifestations of FAP (Used with permission and adapted from  the American Gastroenterology Association Institute's Clinical Teaching Unit 11, copyright) Figure 3
Panel A illustrates the extracolonic upper gastrointestinal polyp manifestations of FAP (Used with permission 
and adapted from the American Gastroenterology Association Institute's Clinical Teaching Unit 11, copy-
right). Fig. B is a schematic illustration of a "J-pouch", formed from the distal small intestine and attached to the anal sphincter. 
The shorter limb of the "J" acting as a fecal reservoir; Fig. C is an x-ray demonstration of this pouch (Figures provided by Dr. A. 
Deutsch, Petach Tikva and reproduced, with permission of the publishers, from reference [70]: Rozen P, Levin B, Young GP: 
Who are at risk for familial colorectal cancer and how can they be managed? In Colorectal Cancer in Clinical Practice: Prevention, 
Early Detection and Management Edited by: Rozen P, Young GP, Levin B, Spann SJ. London, Ed 2, Taylor and Francis 2002:55-66).
B
A
C
Table 1: Spigelman classification for duodenal polyposis in FAP
Stage 1 Stage 2 Stage 3
Polyp number 1-4 5-20 >20
Polyp size (mm) 1-4 5-10 >10
Histology Tubular Tubulovillous Villous
Dysplasia Low grade Low grade High grade
Stage 0, 0 points; stage I, 1-4 points; stage II, 5-6 points; stage III, 7-8 
points; stage IV, 9-12 points. Points are accumulated for polyps' 
number, size, histology and severity of dysplasia. Stage I (1-4 points) 
indicates mild disease, whereas stage III-IV (7-12 points) implies 
severe duodenal polyposis. Derived from reference [7].Orphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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of FAP and APC germline mutations [22]. Thyroid cancer in
a FAP patient was first described in 1949 by Crail. Young
women (less than 35 years of age) are at particular high
risk of developing thyroid cancer, at a rate of approxi-
mately 160 times that of the general population [23,24].
Attenuated familial adenomatous polyposis (AFAP)
This is a less aggressive variant of FAP that is characterized
by fewer colorectal adenomatous polyps (usually 10 to
100), later age of adenoma appearance (mean age of
polyp diagnosis is 44 years) and cancer (mean age 56
years). Clinically, it can be confusing as often there is
mainly proximal colonic involvement with polyps, and
infrequent rectal involvement. Thus, it can be misdiag-
nosed as occurring in a patient with sporadic adenomas
(Figs. 5A-C) however, it can also occur in families with
members having full clinical features of FAP.
Although these individuals have a smaller polyp burden
relative to classic FAP, they still have an increased risk of
cancer that, in general, occurs approximately 10-15 years
later. As in FAP the most prominent extracolonic findings
are upper gastrointestinal polyps specifically, duodenal
and gastric adenomas and fundic gland polyps. Gastric
and breast adenocarcinomas, as well as hepatoblastoma,
have also been documented in AFAP. Other extracolonic
manifestations of FAP are rare [25].
Etiopathogenesis
FAP is a genetic disorder resulting from a mutation in the
adenomatous polyposis gene (APC) gene.
Most FAP patients have a family history of colorectal pol-
yps and cancer, however, 25-30% of them are "de novo",
without clinical or genetic evidence of FAP in family
Panel A illustrates the extraintestinal manifestations of FAP (Used with permission and adapted from the American Gastroen- terology Association Institute's Clinical Teaching Unit 11, copyright) Figure 4
Panel A illustrates the extraintestinal manifestations of FAP (Used with permission and adapted from the 
American Gastroenterology Association Institute's Clinical Teaching Unit 11, copyright). Panel B is a panoramic 
jaw X-ray showing mandibular areas of osteoslerosis that can be found in some FAP patients but is not diagnostic of FAP. Panel 
C shows retinal pigmentation (CHRPE) that can be found in some FAP patients but is not diagnostic of FAP.
A
A
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members [26,27]. It is now recognized that this can be
partially explained by being the result of germline mosai-
cism [28]. Classic FAP is inherited as an autosomal domi-
nant trait and results from a germline APC  mutation;
AFAP is mostly caused by specific APC mutations. A subset
of individuals with clinical features of FAP will instead
carry a mutation in the MUTYH gene (to be discussed
later).
The APC gene in brief
APC is a tumor suppressor gene located on the long arm
of chromosome 5 in band q21 (5q21). The coding region
is divided into 15 exons and encodes a large protein (309
kilo-Daltons) [29]. The APC  protein has multiple
domains that mediate oligomerization as well as binding
to a variety of intracellular proteins, which have an impor-
tant role in cell adhesion, signal transduction and tran-
scriptional activation.
Normal APC structure and functions
The APC gene spans a region of 108,353bp (NC_000005).
The mRNA is 10,719 bp long (NCBI# MN_000038) and
has 16 exons. The mRNA codes for a protein of 2,843
amino acids long with a molecular weight of 310 kDa
(NCBI# NP_000029). Most of the amino acids are in the
last exon (exon-16 that is 8,689 bp long with 6,574 bp
coding sequences). Only exons 2-15 are coding exons and
have 653 amino acids and exon 16 has 2,190.
APC is a classical tumor suppressor protein that plays a
central role in Wnt signaling, in part by regulating the deg-
radation of -catenin. Wnt signals influence the stability
of a protein complex containing -catenin, conductin and
GSK3 (glycogen synthase kinase 3). In the absence of Wnt
or the presence of wild-type APC  protein,  -catenin is
degraded. In the presence of Wnt, or the absence of APC
(as occurs in many colon cancers), -catenin target genes
Panel A shows the endoscopic appearance of early FAP and the difficulty in identifying adenomas; Panel B shows the endo- scopic appearance after spraying with dilute Indian ink contrast chromoendoscopy; note the easier identification of small polyps  (Figures reproduced from reference [85]: P Rozen, F Macrae, Familial adenomatous polyposis: The practical applications of clin- ical and molecular screening. Familial Cancer, 2006; 5:227-335, with kind permission of Springer Science and Business Media) Figure 5
Panel A shows the endoscopic appearance of early FAP and the difficulty in identifying adenomas; Panel B 
shows the endoscopic appearance after spraying with dilute Indian ink contrast chromoendoscopy; note the 
easier identification of small polyps (Figures reproduced from reference [85]: P Rozen, F Macrae, Familial ade-
nomatous polyposis: The practical applications of clinical and molecular screening. Familial Cancer, 2006; 
5:227-335, with kind permission of Springer Science and Business Media). Panel C shows the occasional adenoma 
seen in attenuated FAP and the difficulty in making the endoscopic diagnosis of FAP. Panel D demonstrates the usefulness of 
taking random biopsies in attenuated FAP and finding an intramucosal microadenoma, consistent with the diagnosis of FAP. 
Note the appearance of dark stained and elongated dysplastic nuclei in a distorted crypt that does not protrude above the sur-
rounding normal surface epithelium (Figures reproduced, with permission of the publishers, from reference [70]: Rozen P, 
Levin B, Young GP: Who are at risk for familial colorectal cancer and how can they be managed? In Colorectal Cancer in Clinical 
Practice: Prevention, Early Detection and Management Edited by: Rozen P, Young GP, Levin B, Spann SJ. London, Ed 2, Taylor and 
Francis 2002:55-66.
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including c-myc are expressed. Myc expression, in turn,
leads to the expression of the polyamine ornithine decar-
boxylase (ODC) which is a proto-oncogene (Fig. 6). The
APC gene product indirectly regulates transcription of a
number of critical cell-proliferation genes, through its
interaction with the transcription factor -catenin. APC
binding to -catenin leads to ubiquitin-mediated -cat-
enin destruction; loss of APC function increases transcrip-
tion of -catenin targets. Homozygous APC  truncation
has been shown to affect chromosome attachment in cul-
tured cells. Roles for APC  in cell migration have been
demonstrated in-vitro and in mouse models.
Disturbed APC structure and functions in brief
More than 300 different types of mutations are recognized
today as the cause of FAP. Most of these mutations (inser-
tions, deletions, nonsense mutations, etc.), result in a
truncated protein. The most common mutation, occur-
ring in about 10% of FAP patients, is a deletion mutation
in codon 1309, the next most common, occurring in 5%
of the patients, is a deletion at codon 1061.
APC disturbed structure and function in FAP in humans and animal 
models
Loss of normal APC function is known to be an early event
in both familial and sporadic colon cancer pathogenesis,
occurring at the pre-adenoma stage [30]. Generally, colon
cancers show either chromosomal instability (CIN),
which correlates with loss of APC function, or microsatel-
lite instability, which correlates with loss of mismatch
repair function, but not both. The genetically manipu-
lated mouse model provides an excellent in-vivo system of
human diseases and an opportunity to test therapies. The
mouse model of FAP contains a point mutation in the
APC gene; it develops numerous adenomas and was the
first model used to study the involvement of the APC gene
in intestinal tumorigenesis. The model has provided
examples of modifying loci in mice and demonstrating
the principle of genetic modulation of disease severity
[31].
FAP is caused by a highly heterogeneous spectrum of
point mutations and this represents a problem for molec-
ular genetic diagnosis; all the mutations are chain termi-
nating. Mutations typically cluster in, or just distal, to the
armadillo repeat region and truncate near the middle of
the protein [30,32] (Fig. 7). It is not known which is
pathophysiologic - absence of the full-length protein or
presence of the truncated version; evidence exists for both.
Mutational analysis of the APC gene indicates that the
majority of germline mutations found in patients with
FAP are nonsense mutations, leading to the formation of
a truncated protein. More than 60% of APC mutations are
found in the central region (between codons 1284 and
1580) of the protein, which is called the mutation cluster
region (MCR) [33]. The MCR region coincides with a
region in the APC gene that is important for the down-reg-
ulation of -catenin, which suggests that this function is
important for the pathogenesis of CRC. Subsequent stud-
ies demonstrated that APC and -catenin are important
parts of the Wnt signaling pathway (Fig. 6). The 5' coding
region of exon 15 includes a second mutation-cluster
region. In addition, there are several recurrently described
mutations, of which two, at codon positions 1309 and
1061, account for as much as 30% of the germline APC
mutations. The vast majority of mutations found in the
APC  gene represent truncating mutations (small dele-
tions, 46%; small insertions, 10%; nonsense mutations,
28%). However, missense mutations (3%) and gross
alterations (13%) have also been reported [34]. Recent
data suggest that gross alterations in the APC gene may
contribute more to this disease than previously reported;
perhaps as many as 20% of FAP families may have a gross
alteration.
Genotype-phenotype correlations in brief
Some correlation does exist between the sites of specific
genetic mutations and the clinical manifestations of the
disease, however, this correlation is not exact and differ-
ences do occur (to be discussed later) [35,36] (Fig. 7).
Relationship between Wnt signaling and the APC tumor-sup- pressor gene in activating the -catenin to enter the nucleus  (no APC activity) for promoting genes expression and  polyamine metabolism (ODC) in the colonic epithelium; or  (with APC activity) for the proteasomal degradation in the  colonic epithelium Figure 6
Relationship between Wnt signaling and the APC 
tumor-suppressor gene in activating the -catenin to 
enter the nucleus (no APC activity) for promoting 
genes expression and polyamine metabolism (ODC) 
in the colonic epithelium; or (with APC activity) for 
the proteasomal degradation in the colonic epithe-
lium.
wnt
CONDUCTIN APC
GSK3  CATENIN
NUCLEOUS
 CATENIN
TCF-4 Target  genes e.g c-MYC
MYC target genes
e.g.ODC
-W N T /  + A P C + WNT/ -APC
Proteasomal degradationOrphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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Mutations contributing to classical FAP occur between
exon 5 and the 5' portion of exon 15, whereas those asso-
ciated with AFAP tend to cluster in the extreme 5' portion
of the gene and the 3' portion of exon 15 proximal to
codon 1517 or distal to codon 1900 [35,36]. Mutations
between codons 1250 - 1464 are associated with profuse
polyposis. Mutations at specific positions can cause
CHRPE [37]; it is almost always absent if the protein-trun-
cating mutation in the APC gene occurs before exon 9, but
is consistently present if it occurs after this exon. Patients
with a mutation between codons 1445 - 1578 do not
express CHRPE, but can develop severe desmoid tumors
[38].
Diagnosis
The diagnosis of classic FAP is based on a suggestive fam-
ily history and clinical findings. Whenever possible, the
clinical diagnosis should be confirmed by genetic testing.
Clinical diagnosis
The clinical diagnosis is dependent on the physician's sus-
picion and awareness. The patient may be completely
asymptomatic and obtaining a detailed family cancer his-
tory is essential for a correct diagnosis, since in most cases
some grandparents, parents and siblings will be affected.
Asking simple questions like "has anyone in your family
had cancer? Which cancer? And at what age?" is important
information. Alternatively, rectal bleeding or abdominal
complaints may develop depending on the stage of dis-
ease i.e., polyp burden or stage of cancer. For the astute
physician, identification of extra-colonic manifestations
can lead to performing endoscopic examination of the
large bowel. For example, identifying a desmoid or a man-
dibular osteoma in an individual should lead to a work-
up for ruling-out FAP. This should initially be done by
taking a detailed extended family history and performing
a sigmoidoscopy or a full colonoscopy depending on the
age of the patient or whether we suspect FAP or AFAP.
APC protein functional domains, several of the common mutations and their locations, in relation to the different FAP pheno- types Figure 7
APC protein functional domains, several of the common mutations and their locations, in relation to the differ-
ent FAP phenotypes.
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During childhood, only diminutive adenomas may be
found, limited mainly to the rectosigmoid area of the
colon, by a flexible sigmoidoscopy (Fig. 2A). Random biop-
sies can visualize intra-mucosal adenomas (Fig. 5D). As
age progresses, hundreds of colorectal adenomas and, in
some patients, adenomas in extracolonic locations may
be found (as described previously) (Figs. 2B and 3A).
The diagnosis of AFAP is more complex than that of clas-
sic FAP because of the wide phenotypic variation of dis-
ease. Total colonoscopy, rather than sigmoidoscopy, has
been advocated for screening individuals at risk as the pol-
yps tend to have a right-sided distribution [25]. Chro-
moendoscopy (Fig. 5A and 5B) is recommended to
highlight the polyp burden. As in FAP, the diagnosis of
AFAP is based on the combination of clinical findings and
genetic tests.
Genetic testing is mainly used for screening and the pre-
symptomatic early diagnosis of at-risk family members. In
addition, confirmation of the diagnosis in patients with
obscure clinical findings is essential. At first, only the
index case should be tested and because of the long time
it can sometime take to receive the answer to the initial
mutation analysis, and even if no mutation is identified,
first-degree relatives should be managed clinically until
results are obtained. If the mutation has been identified,
it can be quickly and cheaply performed to screen at-risk
relatives.
Genetic tests in brief
Today, a number of genetic tests are available to test for
APC germline mutations. Among these are sequencing of
the full APC gene, combination of conformation strand
gel electrophoresis (CSGE) screening and protein trunca-
tion test (PTT), protein truncation test alone and finally
linkage analysis. The most commonly used today is direct
sequencing of the APC gene.
The mutation detection rate, when full gene sequencing is
performed, is 70%. Large insertions and deletions need
other tests and add about 5%. MUTYH mutations (see
below) are responsible for a subset of the remaining cases.
When the family's specific APC  mutation is identified,
genetic testing of all first degree relatives should be per-
formed even when the parents test negative [28,35,39].
Parents of children at-risk should be advised that genetic
testing is recommended just before puberty or preferably
in mid-adolescence, when the diagnosis begins to gain
clinical importance in terms of cancer prevention i.e. sur-
gical intervention, and the child is mature enough to
understand the reason for a test and is compliant for eval-
uation. The managing clinician will occasionally ask for
an earlier test if there are suspicious symptoms in the child
or extreme anxiety of the parents. Family members who
test negative for a known mutation do not need further
investigation or follow-up other than standard average-
risk screening.
In approximately 20-30% of patients no germline muta-
tion can be found, although the success is improving with
extensive testing. In this circumstance, no genetic testing
is useful or necessary in any family members; clinical diag-
nosis and systematic surveillance is mandatory for all first
degree relatives.
The genetic alteration in AFAP is associated with APC
mutations occurring most commonly at the 5' or at the 3'
end of the gene proximal to codon 1517 or distal to codon
1900 [39]. Thus, DNA sequencing is usually recom-
mended. The indication for genetic testing include: clini-
cal criteria that meet AFAP or having a first-degree relative
with a known APC mutation or multiple adenomas.
Tests for FAP: why the different methods, why the testing 
is complex and not always complete and why it can be 
expensive?
The relatively long mRNA makes the screening process for
the identification of point mutations by direct sequencing
a labor intense and costly method (about 30 PCR frag-
ments are needed to cover all coding exons sequences).
Mutation detection in the APC gene can be performed
using different methodologies. Selection of the methodol-
ogy depends on the availability of the resources in the lab-
oratory and number of samples analyzed at that time [33].
Several clinical laboratories currently use the RNA based
(PTT), also known as the in vitro-synthesized protein assay
(IVSP), which has a sensitivity ranging from 70% to 90%.
However, the disadvantages of the PTT approach include
decreased RNA stability in blood lymphocytes, assay arti-
facts, and an inability to detect non-truncating mutations.
Additionally, not all laboratories actually characterize
(i.e., sequence) the putative mutation implicated by a PTT
alteration.
Less popular methods of heteroduplex analysis include
analysis of single-strand conformation polymorphisms
(SSCP), conformation-sensitive gel electrophoresis
(CSGE), denaturing gradient gel electrophoresis (DGGE)
and sequencing the entire coding region of the APC gene.
Mutation scanning using denaturing high-performance
liquid chromatography (DHPLC) is a highly sensitive
method [40], and has been used effectively to screen for
mutations in a number of genes [41]. This methodology
is useful in a low- to medium-throughput laboratory.
When this apparatus is not available, sequencing is the
gold standard for mutation detection. Sequencing of theOrphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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entire coding region of the APC gene is only economical
in very high-throughput laboratory with a dedicated
sequencer and appropriate sequence analysis software.
Approximately 20% of classic FAP patients and 70% to
80% of AFAP cases are negative for an APC/MUTYH (see
below) point mutation. Therefore, techniques are used for
detecting copy number alterations (big deletions or inser-
tions, such as a whole exon or several exons), like using
the multiplex ligation-dependent probe amplification
(MLPA) method [42]. Real-time fluorescent PCR also
allows rapid detection of dosage differences of one versus
two copies of the APC gene. This methodology permits
the detection of gross alterations in the APC gene simulta-
neously with amplification, unlike multiplex PCR or
other methodologies such as Southern blotting.
Genetic differential diagnosis-MUTYH, in brief
A subset of patients that presents with clinical AFAP har-
bor a recessive disorder caused by the inheritance of muta-
tions in the base-excision-repair gene MUTYH  [42]. In
health, it encodes a protein responsible for the excision of
adenosine mismatched with a product of DNA damage
caused by reactive oxygen species.
MUTYH mutation causes the polyposis condition known
as MUTYH Attenuated FAP (MAP). It is recessively inher-
ited and patients have either a homozygous or compound
heterozygous germline mutations of the MUTYH gene. In
one series of cases biallelic germ-line MUTYH mutations
were found in 18% of APC  gene mutation-negative
patients with attenuated phenotype [43].
It is recommended that patients, who have a recessive
family history compatible with AFAP, be evaluated for a
MUTYH mutation. There are reports that patients hetero-
zygous for MUTYH  may also develop a phenotype of
polyposis and because of the high carrier rate, ~1%, there
can be compound heterozygotes of uncertain clinical sig-
nificance [44-46].
Normal MUTYH structure and functions in humans
The MUTYH gene - formerly MYH, encodes a DNA glyco-
sylase enzyme which is involved in oxidative DNA dam-
age repair. The enzyme is involved in base excision repair
(BER), and excises adenine bases from the DNA backbone
at sites where the adenine, after the DNA replications, was
inappropriately paired with guanine, cytosine, or 8-oxo-7,
8-dihydroguanine (8-oxoG) which is recognized and cat-
alyzed by the MUTYH protein [47]. The protein is local-
ized to the nucleus and mitochondria [48]. Multiple
transcript variants encoding different isoforms have been
found for this gene [43]. The MUTYH gene contains 16
exons spanning a region of 11147 bp, but only 15 are cod-
ing exons [2-16], and it maps to chromosome 1p32-34.
The transcribed mRNA is 1854 bp long (NCBI#
NM_102222.2) and it encodes a protein with 546 amino
acid (NCBI# NP_036354.1) and has a molecular weight
of 52 kDa. The protein contains several functional
domains including: the N-terminal domain on the 5' side
which contains the catalytic region and includes a helix-
hairpin-helix (HhH), pseudo HhH and an iron-sulfur
cluster loop motif, which are also common motifs in
other BER glycosylases; the C-terminal domain on the 3'
side shares homology with MTH1 (member of the base
excision repair (BER) family) and plays a role in 8-oxoG
recognition. The MUTYH has also binding sites for a DNA
binding domain, an adenine binding motif and several
interaction domains for apurinic endonuclease 1 (APE1)
enzyme, proliferating-cell nuclear antigen (PCNA), repli-
cation protein A (RPA) and MSH6, located in different
regions of the gene (Fig. 8).
MUTYH - disturbed structure and associated polyposis 
(MAP)
DNA alterations in the MUTYH  gene at functional
domains can alter the proper protein function or abort it
completely [49]. For example, one alternative splicing
mutation can generate a gene product of 521 amino acids
(instead of 546) and is referred to as type 2. Type 1 is
transported to the mitochondria, while type 2 lacks the
first exon containing a mitochondrial targeting signal
(MTS) and is transported to the nucleus.
Mutations in this gene result in a heritable predisposition
for colon and occasionally stomach cancers [49]. MUTYH
associated polyposis is mostly an autosomal recessive dis-
order, the frequency of heterozygotes carriers is 1-2% and
the frequency of bi-allelic mutation carriers lies between 1
per 10,000 and 40,000 births. The penetrance for colon
polyps is close to 100% and bi-allelic MUTYH mutation
carriers generally develop 10-100 adenomatous polyps/
adenomas of the colon and rectum [49]. In some hetero-
zygous MUTYH mutation carriers (apparently a dominant
form of MAP), a slightly increased risk for developing
CRC has been found [45,46]. Approximately one third of
patients also develop polyps/adenomas in the upper gas-
trointestinal tract [50].
Because of the development of multiple polyps, the risk
for CRC is high and 60-70% of MAP CRC patients were
first diagnosed at a mean age of 47 years. When frequent
colorectal and upper gastrointestinal tract screening is per-
formed in a MAP-patient who has not developed cancer,
the chance of developing carcinoma is small and progno-
sis will be comparable to that of a healthy population.Orphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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MUTYH-genotype/phenotype correlations to "FAP" 
features
A large proportion of non-FAP non-Lynch syndrome
patients with multiple colorectal adenomas have germline
mutations on the MUTYH gene. Although the number of
adenomas appears to be dependent on the number of
mutated  MUTYH  alleles present in a patient, little is
known on the relation of this number with cancer risk.
This recently recognized type of adenomatous polyposis
was first documented in a Welsh family having bi-allelic
germline mutations [51]. Similar findings were subse-
quently confirmed in other subjects of European origin
having multiple colorectal adenomas ranging from 5 to
several hundreds [52]. There are some ethnic specific
mutations. While the mutations Y165C and G382D are
the most common in Europeans, the Y90X mutation
occurs in subjects of Pakistani origin, whereas an E466X
mutation has been found in subjects of Indian origin [43].
An in-frame deletion nt1395-7delGGA has been
described in Italian populations [53]. Baglioni et al. 2005
identified in a brother and sister, the offspring of first-
cousin parents, an association of multiple adenomatous
polyps of the colon with childhood pilomatricomas, a
homozygous 2-bp insertion in exon 13 of the MUTYH
gene, 1186insGG, resulting in a frame shift and a prema-
ture stop codon at position 438 [53]. The brother also had
early-onset rectal adenocarcinoma. In a large screening of
453 APC-negative patients with more than five colorectal
adenomas, it was found that pathogenic mutations were
initially found in 74 patients without extra-digestive
tumors (22.5%) and subsequently in 75 at-risk relatives
[46]. Polyposis was more severe in cases with bi-allelic
mutations. However, mutation copy number was corre-
lated neither with the age at diagnosis of adenomas or
Diagram of the MUTYH protein in scale; known functional domains (the filled boxes) data derived from Sampson et al, 2005  [43]; and three types of well known typical mutations - missense or in-frame, splice and truncation Figure 8
Diagram of the MUTYH protein in scale; known functional domains (the filled boxes) data derived from Samp-
son et al, 2005 [43]; and three types of well known typical mutations - missense or in-frame, splice and trunca-
tion. APE1, apurinic endonuclease 1; HhH, helix-hairpin-helix; PCNA, proliferating-cell nuclear antigen; RPA, replication 
protein A.
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adenocarcinomas, nor with the presence of a family his-
tory of colorectal tumors. Heterozygous and homozygous
MUTYH mutation carriers were both at high risk for syn-
chronous cancers (24% in the colorectum and 16% in the
upper gastrointestinal tract), but did not demonstrate an
increased risk for extra-digestive tumors [46]. Recently, it
has been demonstrated that MUTYH polyps may not only
be adenomas, but also sessile serrated adenomas and
hyperplastic polyps [54]. These do not exclude the diag-
nosis of a MUTYH mutation.
Tests for MUTYH
Genetic testing for MUTYH  mutation has been recom-
mended for all patients who have tens to hundreds of
colorectal adenomas with no identified germline muta-
tion in the APC gene and with a family history compatible
with an autosomal recessive mode of inheritance. MUTYH
associated polyposis is a frequent inherited CRC predispo-
sition, which can be mostly in a recessive form of inherit-
ance (bi-allelic or compound mutations) but also as a
dominant component, and therefore DNA screening of
the MUTYH gene should look for both heterozygous and
homozygous mutations [46]. Mutations screening can be
done by direct sequencing of the entire coding region of
the MUTYH gene, but this is time-consuming and costly
(sequencing 15-16 PCR fragments in a bidirectional way).
DNA chromatography (DHPLC) as first line of screening
could be applied by subjecting PCR products to chroma-
tography using an ion-pair reversed-phase cartridge. PCR
products are denatured and allowed to re-anneal. Under
conditions of partial denaturation with a linear ace-
tonitrile gradient, heteroduplexes from PCR samples hav-
ing an internal sequence variation display a reduced
column retention time relative to their homoduplex coun-
terparts. The elution profile for heterozygous samples is
typically quite distinct from that of either homozygous
sequence, making the identification of heterozygous
mutations relatively straightforward [42]. An analysis for
homozygous autosomal mutations requires mixing the
test sample with the DNA of a known sequence [55].
Approximately 20% of classic FAP cases and 70% to 80%
of AFAP patients are negative for the APC/MUTYH point
mutation. Therefore, techniques for detecting copy
number alterations should use MLPA [56].
What to test for first: APC or MUTYH mutation?
Because the carrier mutation rate in the MUTYH gene, is
about 1% of patients with low or mild polyposis and it
has been found that heterozygous MUTYH mutation car-
riers can have an increased risk for developing CRC (espe-
cially in MAP patients aged >55 years), this can be a
dilemma. If the patient's phenotype and family history are
compatible with FAP, one should start by screening the
APC, as this gene is more likely to be mutated then the
MUTYH.
One can combine testing for the two genes when planning
a strategy for screening both in polyposis patients. Screen
the sequences of the APC exons 2-15 and 2,500 bp of the
5' of exon-16 together with the 15 coding exons of the
MUTYH  gene and only when no mutations are found
then to continue to screen the rest of the APC (exon-16,
the 3' end which has 4076 bp and infrequent mutations).
DNA chromatography can be used to reduce the time and
cost for this type of screening. If no mutations are detected
in both genes, one can continue to do MLPA, but this
method is relatively expensive.
If the mutations that were found in one of these MUTYH
genes are heterozygous mutations, only then should the
second gene be screened, as one heterozygous mutation
does not usually fully explain the different phenotypes
(number of polyps, colonic distribution, age of onset,
family history). Two severe mutations in both genes
might have a cumulative effect and a strong clinical
impact that could lead to illness at a young age and the
phenotype will be more severe. We estimate that a muta-
tion in the APC gene will be more severe then mutation in
the MUTYH gene, as the APC gene is part of the Wnt path-
way and can influence several cellular functions such as
proliferation, differentiation, apoptosis, adhesion, migra-
tion, and chromosomal segregation. While MUTYH is an
enzyme that fixes damage in the DNA after replications,
and more then 90% of DNA is not a coding or regulatory
element of the genome, so most of the DNA replication
mistakes, will not have a prominent effect.
Differential diagnosis of FAP
There are other disorders causing multiple polyps. These
include hamartomatous polyps such as those in Peutz-
Jeghers syndrome (mainly in the small bowel but may
occur anywhere along the gastrointestinal tract), familial
juvenile polyps or hyperplastic polyposis and hereditary
mixed polyposis syndromes. Multiple lymphoid aggre-
gates can masquerade as early FAP, especially in children
and young adults. The diagnosis depends on the correct
histological classification of the polyps. Dysplastic
changes occurring in a non-adenomatous polyp can be
mistakenly identified as a multiple adenoma syndrome
compatible with FAP. The combination of adenomatous
polyps and an autosomal dominant pattern of inheritance
is classic for FAP and rules out most of the alternative pos-
sibilities. At times it is difficult to differentiate between
AFAP and Lynch syndrome (hereditary non polyposis
colorectal cancer as both may have a low polyp burden,
occurring mainly in the right colon. The differentiation
from MAP is discussed above.Orphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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Genetic counseling and socio-legal aspects of 
FAP
FAP is a hereditary condition, so referral to a geneticist or
genetic counselor is mandatory [1,57]. FAP is a dominant
syndrome caused when one copy of the APC gene con-
tains a fault; this means that every child of a FAP patient
has a 50% chance of inheriting the faulty gene. There is a
risk of FAP in first-degree family members who may also
be symptomatic or even asymptomatic at the time of diag-
nosis in the propositus. The risk to the siblings depends
on the genetic status of the parents who need to be evalu-
ated for carrying the mutation. As mentioned above,
because of germline mosaicism, this does not exclude sib-
lings being affected and they should also be evaluated
genetically [23]. About 20-30% of probands have a de
novo mutation.
The diagnosis of FAP, with or without an identified
genetic mutation can lead to guilt, anxiety, cancer phobia,
denial and refusal to collaborate. These patients and their
families need a treating physician who understands the
complexity of their condition and can provide clear
advice. Affected children, who have not been adequately
counseled, may develop antagonistic feelings towards the
disease-transmitting parent and they may need help from
a child psychologist who understands the medical prob-
lem, especially if they need to undergo a potentially trau-
matic or mutilating procedure such as creation of a stoma.
As many of the patients may be underage, informed con-
sent from the parents must be obtained for all genetic test-
ing and other invasive procedures. Whenever possible the
child should also be given an explanation and understand
why the testing is being performed [58]. So, a geneticist or
genetic counselor is needed prior to genetic testing, and is
also important when dealing with prenuptial young
adults. Not involving the future spouse can lead to
extreme strains on intra-familial relationships when the
medical condition and risk for FAP and, or, cancer in the
patient and children becomes known.
The genetic information is not only relevant to the
affected patient, but also to the immediate family and
even to future descendants. This leads to ethical dilemmas
and patients, for personal or religious reasons, may even
refuse to allow the information to be provided to the
unsuspecting immediate family at risk [59,60]. Failure to
obtain a relevant family history and instructing the family
on their risk and need for follow-up can be considered
medical negligence [61]. However, it is not clear how this
can be done without the patient's consent. Another com-
mon problem is that by identifying an asymptomatic per-
son at-risk and needing diagnosis and follow-up could
lead to losing a job and medical and life insurances
[62,63]. These fears inhibit the patient's cooperation and
these problems need to be addressed by legislation.
Prenatal diagnosis, pregnancy and genetic 
counseling
Identification of the mutated APC gene responsible for
FAP enables presymptomatic and even prenatal diagnosis
of the disease. If a mutation is identified in a family mem-
ber then prenatal testing can be performed. Conventional
prenatal diagnosis such as amniocentesis and chorionic vil-
lous sampling (CVS) could indicate whether a fetus is
affected, giving the option to selectively terminate the
pregnancy. The question that arises is how acceptable is
prenatal diagnosis and pregnancy termination among
FAP kindred? The answer to this complex question will be
influenced by experience with the disease, psychological
as well as cultural and religious attitudes. In the UK, 62
adults were questioned regarding antenatal testing and
only 24% of those questioned stated that they would pro-
ceed to termination of pregnancy if a prenatal test indi-
cated that the unborn baby was affected; however, in
clinical practice this was not requested [64]. A study that
included 20 FAP patients found that 90% would consider
preimplantation genetic diagnosis, 75% would consider
amniocentesis or CVS. Having an affected child and expe-
riencing a first-degree relative's death due to FAP were
associated with greater willingness to consider prenatal
testing [65]. Another study [66], that included younger
individuals and individuals "at risk" for FAP, found that
although 75% would consider prenatal genetic testing
only 21% would consider termination of an affected preg-
nancy. The predictive testing of a fetus for a disease that
has an affect on quality of life, as well as early mortality,
should be offered to couples who would be willing to
avoid the birth of an affected child or terminate a preg-
nancy at an early stage.
Amniocentesis, the test that is most commonly used, is
performed between 16 and 20 wk of gestation. A small-
bore needle is inserted through the abdomen and uterus,
into the amniotic sac, usually with ultrasound guidance,
and approximately 30 mL of amniotic fluid is drawn for
analysis. CVS allows for earlier test results and is per-
formed between 10 and 12 wk. CVS is usually performed
trans-cervically, with ultrasound-guidance, a thin plastic
tube is inserted into the placenta and a small sample of
chorionic villous tissue is withdrawn by suction. The risk
of miscarriage estimated to be between 0.25-0.5% for
amniocentesis and 0.5-1.0% for CVS [67].
An additional alternative to prenatal diagnosis and termi-
nation of pregnancy is preimplantation genetic diagnosis
(PGD). This method enables genetically affected individ-
uals to produce healthy fetuses, by selection of embryos
that are free of the genetic mutation that leads to FAP. By
ensuring unaffected pregnancies, PGD avoids early preg-
nancy termination with all that is involved. PGD, even if
subject to controversy, expensive and not easy to performOrphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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(both for the patient and laboratory), seems to be a more
acceptable option than prenatal diagnosis.
Two methods for PGD have been recently developed and
implemented in the framework of in-vitro  fertilization.
PGD can be performed by micromanipulation and biopsy
of the first polar body before fertilization, or by blasto-
meric biopsy before implantation of the pre-embryo.
Available data suggest that preimplantation diagnosis is
safe, as no detrimental effects have been observed in stud-
ies on the viability of biopsied pre-embryos. Genetic anal-
ysis of biopsied gametes and blastomeres is now possible
by DNA analysis, while enzyme analysis and preimplanta-
tion diagnosis of chromosomal disorders are still at the
research stage. The accuracy of DNA analysis in preim-
plantation diagnosis is clear from available data on the
outcome of these pregnancies. To date, children free of
genetic diseases have been born following preimplanta-
tion diagnosis of cystic fibrosis, hemophilia A, FAP, and
other conditions. In individuals with FAP, Moutou et al.
[68] reported 11 cycles that were performed for four cou-
ples, resulting in eight embryo transfers and five pregnan-
cies, with the birth of one healthy boy and two ongoing
pregnancies. In Australia, Davis et al. in 2006 reported
performance of PGD. After standard IVF hormonal treat-
ment 14 oocytes were collected, 11 inseminated and nine
embryos were biopsied on day 3. Of the nine embryos
that were analyzed, five embryos were affected and four
were unaffected. Two unaffected embryos were transferred
on day 4 resulting in a triplet pregnancy and the birth of
three healthy babies [69]. Today, PGD is an acceptable
and potentially preferable method to reduce the birth risk
of babies affected with FAP.
Pregnancy
During pregnancy, due to the endogenous multiple
growth factors and hormones, there is an increase rate of
desmoid and adenoma development in the mother. How-
ever, if possible, therapies should be delayed until preg-
nancy has ended so as to avoid the possibility of fetal
damage.
Management of the FAP patient
Cancer prevention and maintaining good quality of life
are the main goals in management of patients with clini-
cal or genetic evidence of FAP. Large bowel endoscopy is
the most important clinical examination since there is
almost a 100% chance of CRC. However, as discussed pre-
viously, the disease is systemic with extracolonic manifes-
tations and should be looked for by systematic
reexaminations [11,70,71]. CRC is rare in the asympto-
matic youth, so after their genetic diagnosis and baseline
sigmoidoscopy, they are systematically followed clinically
until completing schooling and growth and maturing.
Around ages 16-18 y patients with FAP should be fol-
lowed by annual or less frequent colonoscopic examina-
tions (depending on the polyp burden at last
colonoscopy) and all significant sized adenomas should
be removed if surgery is not contemplated at that time. In
addition, both forward-viewing and side-viewing upper
tract endoscopies should be performed prior to surgery or
every 1 to 5 years depending on the polyp burden and Spi-
gelman stage (Tables 1 and 2) [8,72] to detect gastric but
mainly duodenal and periampullary adenomas, respec-
tively.
Usually, by the late teens or early twenties, due to the
increasing number of adenomas, prophylactic cancer-pre-
ventive colorectal surgery is advocated [27,72-74]. Since this
is an elective procedure the timing can be arranged to be
the least inconvenient for the patient and family. Elective
surgery, can at times, be delayed if the patient is compliant
and polyps are sparse and not large.
Surgical options include subtotal colectomy with ileorectal
anastomosis  (IRA), total proctocolectomy with ileostomy,
and proctocolectomy with or without mucosectomy and
ileal pouch anal anastomosis (IPAA) [75-77].
Given the substantial risk of rectal cancer developing after
colectomy and ileorectal anastomosis, most experts advise
total proctocolectomy for the typical FAP patient with
multiple rectal adenomas [77-79]. This surgery includes
removal of the entire large bowel and striping of the
remaining rectal mucosa down to the dentate line if there
are multiple polyps or leaving a cuff of rectal mucosa, and
forming an internal pouch from the ileum. Because of bet-
ter bowel control after such surgery, many colorectal sur-
geons prefer the stapled rather than the hand-sewn
anastomosis. So, if there is no severe rectal polyposis this
Table 2: Recommended surveillance interval intervals between gastroscopy examinations
Spigelman 0 and I: Endoscopy at intervals of 5 years
Spigelman Stage II: Endoscopy at intervals of 3 years
Spigelman Stage III: Endoscopy at intervals of 1-2 year
Consider endoscopic ultrasonography
Consider celecoxib 800 mg/d
Spigelman Stage IV: Endoscopic ultrasonography (EUS)
Consider surgery: Pancreas-sparing or pylorus-sparing duodenectomy
Source, reference [12]Orphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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is the most common pouch operation. However, this
requires careful biannual or annual examination and
removal of adenomas that can recur there [80]. This sur-
gery is called total proctocolectomy with ileoanal J-pouch
and it is the surgical procedure of choice for most patients
with classical FAP [79] (Figs. 3B and 3C).
In cases with few rectal polyps, IRA can be a suitable alter-
native procedure providing there is acceptance of life-long
rectal surveillance [75]. Many prefer this procedure for
women with a low polyp burden since it has been
reported that pouch procedures can reduce fertility
[81,82]. Later conversion of an ileorectal anastomosis to a
J-pouch can be performed, but may be difficult because of
desmoid formation in the operated area.
Post-colectomy surveillance
It is important to emphasize that follow-up is vital after
surgical procedures are completed. Initially, it should be
at short intervals to asses the psychological and physical
adaptation to surgery and identify desmoid tumor forma-
tion in its earliest stage. The initial follow-up should
include a thorough physical examination, baseline
abdominal ultrasound (US) or computed tomography or
magnetic resonance imaging (CT or MRI) to aid in detect-
ing existing or future changes suspicious of a desmoid
tumor. Patients after stapled and hand sewn IRA are at risk
for rectal adenomas and carcinomas. Therefore, the physi-
cian needs to stress the importance of endoscopic annual
surveillance of the pouch. Many studies have shown that
adenomas and occasionally even adenocarcinomas have
been found in the ileo-anal pouch after restorative procto-
colectomy (Figs. 9D and 9E). Therefore, surveillance of
the pouch [80,81,83] and transitional anal zone [84] is
essential.
Quality of life after surgery
Since surgery is an elective procedure in FAP, the treating
specialist has the opportunity to educate the patient
regarding the specific procedure and quality of life that
should be expected post-surgery so as to minimize fear
and reduce expectations. This can be facilitated by meet-
ing patients of the same sex and similar age group who
have had a similar procedure performed, and occasionally
a sympathetic psychologist can be helpful in overcoming
fear [70,85]. There are many reports showing that most
patients are satisfied following an IPAA procedure
[82,86,87]. However, patients should be advised that
although fecal elimination via the anus will be preserved,
functional outcome may vary and is not comparable with
bowel elimination prior to surgery. Pouchitis is a major
cause of morbidity and discomfort in patients undergoing
IPAA for ulcerative colitis (15-20%), however, this is rare
in FAP patients (0-10%).
The majority of patients with FAP develops adenomatous
polyps and requires preventive surgery during their late
teens or early twenties. These years are the main reproduc-
tive years and maintaining sexual function is of major
concern. Sexual impairment following proctectomy is
largely technique-dependent and this should be discussed
with the surgeon performing the procedure [82]. For men,
denervation of the pelvic plexus is the major cause of erec-
tile and ejaculation dysfunction. Following an IPAA, erec-
tile dysfunction is reported to occur in 0-1.5% of patients,
while ejaculation dysfunction occurs in 3-4% of these
individuals [86-89].
In woman, sexual dysfunction is less obviously disturbed,
mostly due to the fact that it is more difficult to measure.
In addition, there is a lack of reporting of discomfort as
well as dysfunction. Dyspareunia is a major concern and
in different reports affects between 3-22% of the patients
[81,88,89]. This may be due to anatomical changes within
the pelvis following proctectomy. Approximately 3% of
woman report avoidance of sexual contact due to fear of
fecal leakage. For these reasons surgical experience with
the IPAA procedure is of great importance and patients
with FAP are advised to have the procedure performed in
medical centers that are familiar with FAP and by surgeons
experienced with this procedure. Knowledge about fertil-
ity of women suffering from FAP is scarce and inconclu-
sive. The IPAA procedure does not risk pregnancy but may
reduce fertility. Olsen in 2003 [82] reported that fecundity
dropped to 54% following proctocolectomy with IPAA, a
rate similar to that in patients undergoing IPAA for other
indications although it was greater than the postoperative
fecundity of women with ulcerative colitis. It is thought
that pelvic adhesions after surgery may be responsible for
infertility in FAP woman post IPAA. The significant reduc-
tion in female fecundity after IPAA should be discussed
with women with FAP before it is decided which surgical
option to choose and timing of the operation. If the mild
manifestation of FAP make it possible, and the patient is
compliant for frequent follow-up, then elective surgery
should be delayed until completing the planned family.
Extra-colonic disease
Adenomatous polyps are also found in the stomach and
duodenum, especially the periampullary area and can
develop into adenocarcinomas. After colectomy, periam-
pullary carcinoma is the most common malignancy,
occurring in approximately 5-6% of the patients. It is the
major cause of death in patients with FAP who have had
prophylactic colectomy. For this reason upper endoscopy
with a gastroscope and a side-viewing duodenoscope
should be performed every 1-5 yrs depending on the gas-
tric and specifically duodenal and periampullary polyp
burden. The EUROFAP guidelines for surveillance are pre-
sented in Table 2. After adequate biopsy sampling of theOrphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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lesions to determine the degree of adenoma dysplasia and
endoscopic ultrasound to determine depth of mucosal
involvement, large polyps can be treated with endoscopic
mucosal resection. Argon plasma coagulation is used to
destroy small adenomas and polyp remnants after muco-
sectomy, but when repeatedly performed it causes scaring
and duodenal narrowing which may require dilation
(Figs. 9A-C). Endoscopic ampulectomy can be performed,
but with stenting of the pancreatic duct so as to minimize
post-procedure pancreatitis. There is theoretical, but
unproven evidence that changing the cancer-promoting
bile to ursodeoxycholic acid by saturating it with ursodiol
could be useful. This could be combined with celecoxib.
Documentation of villous changes, severe dysplasia, and
rapid growth of an adenomatous polyp has also been sug-
gested as indications for surgical intervention. Spigelman
stage 4 is an additional indication for surgery. The proce-
dure of choice for many years has been the standard
Whipple procedure. Pylorus preserving duodenectomy,
performed in centers where physicians are familiar and
experienced with this procedure, or pancreas preserving
duodenectomy (PPTD) which includes resection of the
entire duodenum from the pylorus to the ligament of Tre-
itz with preservation of the pancreas have both been suc-
cessfully performed [90,91]. PPTD is a safe surgical
procedure for duodenal adenomatosis, provides high
quality of life, and shows advantages over the pylorus pre-
serving - Whipple procedure [91].
Desmoid tumors occur in approximately 10% of patients
with FAP, more often in women, and are known to be
Panel A shows flat and elevated duodenal adenomas in a FAP patient Figure 9
Panel A shows flat and elevated duodenal adenomas in a FAP patient. These were proven by biopsy and endoscopic 
ultrasound to be free of cancer. Panel B - the polyps were removed by submucosal resection and polypectomy. Panel C - the 
polyp remnants had been destroyed by argon plasma coagulation (figures provided by Dr. M. Santo, Tel Aviv). Panel D shows a 
large polyp that developed, during pregnancy, in the ileo-anal pouch of a FAP patient. Panel E - the polyps had been removed by 
submucosal resection and polypectomy and remnants destroyed by argon plasma coagulation (figures provided by Dr. Z. Halp-
ern, Tel Aviv).
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induced by surgical procedures and pregnancy. They are
major causes of morbidity by compression of organs or
vessels such as ureter or blood supply, can bleed into the
gastrointestinal tract, or if not managed early can cause
death by massive bowel compression. Most of these
tumors have ill-defined borders, are located in the mesen-
tery, areas of scars or bowel wall, but can also be detected
in many other locations. Any suspicious finding on phys-
ical examination requires imaging studies [92]. Treatment
of desmoid tumors should be under supervision of a
multidisciplinary team that includes surgical and medical
oncologists, and gastroenterologists who are familiar with
the disease. Treatment is first aimed at measuring the indi-
vidual's risk from the disease itself and potential benefit of
intervention. Pre-treatment staging based on tumor loca-
tion; size, symptoms and growth behavior are most useful
[93]. In most cases, a period of initial observation to see if
its size is static, regresses or progresses, is an option. There
are no controlled trials of therapies, but there are small
and positive experiences reported with anti-estrogens (e.g.
tamoxifen) [94] and COX-2 inhibitors (sulindac or
celecoxib) in chemoprevention and slowing progression
of the disease; radiation has also shown some effective-
ness [95]. Surgery is performed when necessary, often for
abdominal wall desmoids. Usually, the procedure cannot
completely remove the mass and may actually stimulate
re-growth there or elsewhere. Desmoids bleed on biopsy
(which should be avoided) and surgery, and this is diffi-
cult to control. For tumors managed by surgery the objec-
tive is to achieve tumor free margins (R0) without
sacrificing small bowel. These therapies are most useful
when the lesions are small. Multiple, small case-series
report objective responses to cytotoxic chemotherapy in
severe desmoid disease. These include doxorubicin and
dacarbazine, followed by carboplatin and dacarbazine,
the vinca alkaloids vincristine, vinblastine and vinorel-
bine, and the combination of vinblastine with methotrex-
ate. In a relatively large series of 21 patients with FAP
(Bertagnollia et al. [96]), 93% of patients with progressing
desmoid tumors and unresectable disease achieved dis-
ease response or stability with the combination of cyto-
toxic chemotherapy that included liposomal doxorubicin
as first line therapy and vinorelbine used as second line
and surgery when possible.
To summarize, the optimal management strategy for
desmoid tumors in patients with FAP should be individu-
alized, taking into consideration the extent of disease,
morbidity and potential benefit versus risk of the different
treatment modalities.
Osteomas are common and are usually left alone unless
they are unsightly or interfering with the patient's func-
tion. Therapy is initially as for desmoids, but they might
require reconstructive plastic surgery if disfiguring.
Small bowel adenomas occur and are rarely a problem to the
patient, although cancers have been reported [97]. The
cancer can occur in adenomas close to the duodenal bile-
flow (as discussed earlier) or close to the ileo-anal anasto-
mosis. The role of wireless capsule endoscopy (CE) in sur-
veillance of the asymptomatic patients with FAP is
presently unproven. A small study of 23 individuals with
FAP [15] found 11 patients with duodenal polyps and 7
had jejunal-ileal polyps. CE missed ampulary and many
of the duodenal polyps detected at endoscopy, but were
successful in identifying mid-distal small bowel polyps.
Burke et al. [16] reported that 9 of 15 (60%) of subjects
with FAP had small bowel polyps. The prevalence of small
bowel polyps was related to the duodenal polyposis stage
and subject's age. The location, size and number of polyps
progressed as duodenal polyposis stage advanced [16].
On the other hand, Wong and colleagues [98] from Utah
found that CE underestimated the number of small bowel
polyps and did not reliably detect large polyps. Additional
studies are required before recommendations can be
made.
Other extra-gastrointestinal tumors are rare and have been
reported as pancreatic adenocarcinoma (2%), thyroid
cancer (2%), gastric adenocarcinoma (0.5%), and hepato-
blastoma in children less than 5 years of age (1.6%).
These should be searched for during routine clinical and
imaging follow-up.
There are non-somatic perturbations related to the diag-
nosis and therapy of FAP (see section on Genetic coun-
seling).
Effectiveness of screening
The usefulness of screening asymptomatic FAP patients
for all of its possible manifestations is unproven. For chil-
dren, to identify hepatoblastoma, some recommend
annual alpha-fetoprotein and abdominal ultrasound
from birth until the age of 10 years. For all FAP patients,
an annual physical examination should include an evalu-
ation for soft tissue or bone lesions, and a thorough thy-
roid examination with a low threshold for performing an
ultrasound of any suspicious lesion.
Symptomatic patients (abdominal pain, new onset diabe-
tes mellitus or acute pancreatitis) require evaluation
which could include computed tomography of the abdo-
men to rule out desmoid tumors of the mesentery or pan-
creatic adenocarcinomas (or intraductal papillary and
mucinous tumors (IPMT) of the pancreas [99]. If the CT is
not diagnostic, then magnetic resonance imaging is indi-
cated, it can outline vascular involvement of a desmoid
tumor and may predict its growth [100]. CT of the brain
can also be used in symptomatic patients to search for a
medulloblastoma.Orphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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Individuals with a family history of FAP should be
screened. When a specific APC mutation has been identi-
fied in an index patient all 1st degree relatives carry a 50%
risk of FAP and should be referred for genetic counseling
and offered APC mutation testing. A family member who
is found to carry the mutation has 100% chance of devel-
oping FAP and its complications. It is recommended that
these individuals have a colonoscopy and follow specific
surveillance recommendation that have been outlined for
FAP patients. Children that have been identified as carry-
ing an APC mutation should have a flexible sigmoidos-
copy performed by the age of early adolescence unless
symptoms develop at an earlier stage. When polyps are
detected, discussion with the patient and parents should
take place regarding further surveillance and timing of
surgery as described above.
If genetic testing cannot be performed in a 1st degree rela-
tive of a known mutation carrier, then the asymptomatic
1st degree family member has a 50% chance of harboring
the mutation and should be screened as if they have the
APC mutation. All adults should have colonoscopies per-
formed and all children should undergo a flexible sig-
moidoscopy around the age of 10-12 years [101].
Adenomas develop with the child's growth, and therefore
are easier to identify at adolescence. If polyps are not
found, then there should be annual clinical visits for phys-
ical or ophthalmic evidence of FAP and to assess suspi-
cious symptoms. Sigmoidoscopy should be repeated at
suitable intervals, minimizing its psychological trauma
and maximizing cooperation of the growing child, until
polyps emerge. If by the age of 25 years polyps are not
detected, then biennial sigmoidoscopy or, preferably
colonoscopy, can be done since the likelihood of develop-
ing adenomas decreases as the patient's age increases.
From the age of 35 years, an examination every third year
is recommended until the individual is 50 years old. If
polyps have not been detected by then, the individual
most likely, but not absolutely, doesn't have FAP, and
screening is recommended according to guidelines for the
general population.
When an individual in a family with a known mutation
tests negative, then routine colorectal screening is recom-
mended, as for the general population, beginning at age
50 years.
In approximately 25-30% of patients with clinically evi-
dent FAP a mutation cannot be identified. If available,
MUTYH testing and more complete DNA analyses are per-
formed in specialized laboratories. If these are also nega-
tive, then such individuals are considered to have FAP and
should be treated as such. Gene testing can exclude FAP
only if a mutation is identified in a family member and
this mutation does not exist in a given individual.
Prevention
Diet and lifestyle
The evidence for being able to modulate the clinical man-
ifestations of a dominant genetic disease is indirect and
based on observations in animal models and humans.
Caloric restriction or diet with olive oil, fruits and vegeta-
bles significantly reduced the number of polyps in the
genetically manipulated APC Min mice model [102]. In
the same model, low dosage ursodiol together with sulin-
dac prevented adenomas with less toxicity than if each
had been given alone in full dosage [103].
Clinical observation of FAP families showed that the
severity of disease varied between affected family mem-
bers or between families carrying the same mutation
[104]. This would suggest that not only are there genetic-
genetic/endogenous modulating factors, but there could
be genetic-exogenous modulating factors at play. Ade-
noma expression and growth occurs with aging, effect of
growth factors, hormones, weight gain, diet, tobacco use.
As an example, in two twin boys with FAP there was a clear
correlation between obesity in one twin and adenoma
expression as compared to the other twin (Rozen, person-
nel communication).
So, it would be wise to recommend a "balanced" CRC-pre-
ventive lifestyle and diet from childhood in anticipation
of modulating the clinical expression of FAP.
Chemoprevention
Randomized trials have shown that both sulindac
[105,106] and celecoxib [107] cause regression of estab-
lished adenomatous polyps in individuals with FAP. Spe-
cific cycloxygenase-2 (COX-2) inhibitors, celecoxib and
rofecoxib [108,109], among others, were developed to
overcome the risk of gastrointestinal damage due to
inhibiting the cytoprotective COX-1. In patients with FAP,
treatment with 400 mg of celecoxib twice daily for 6 mo
had been shown to reduce the tumor burden by 28% as
compared to a reduction of 4.5% in the placebo group (p
= 0.003) [107] (Fig. 10). In 2001, the US Food and Drug
Administration approved the use of celecoxib (as an
adjunct to endoscopic surveillance, and surgical manage-
ment) in patients with FAP and having polyps; while the
European Medicines Agency approved an orphan designa-
tion for celecoxib [3]. This agency has also designated
eflornithine hydrochloride, an irreversible inhibitor of
ornithine decarboxilase (ODC), the first and rate-limiting
enzyme in the polyamine synthesis, as an orphan medical
product to be investigated for use in individuals with FAP
[110].
A recent study failed to show that sulindac prevented the
primary development of adenomas in individuals with
FAP [111]. However, although relatively safe in terms ofOrphanet Journal of Rare Diseases 2009, 4:22 http://www.ojrd.com/content/4/1/22
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gastrointestinal toxicity, the long-term use of COX-2
inhibitors in the setting of CRC prevention carries a risk,
albeit small, of serious cardiovascular complications
[112]. Celecoxib/sulindac given for adenomatous polyps
in the retained rectum or duodenum in order to delay
definitive surgery is expensive and intramucosal adeno-
mas and CRC still occurred [105]. This could be due to the
untreated COX-1 found in all adenomas [113]. Adenoma
regression has occurred also with estrogen/progesterone
oral contraceptives [114].
Attenuated FAP
The management of patients with AFAP depends largely
on the polyp burden and their location in the large bowel.
In a patient with few adenomas that can all be removed,
colonoscopic polypectomy is sufficient. Since the ade-
noma-carcinoma sequence in these patients does not
seem to be overly accelerated, a 2 year interval between
colonoscopies, probably for life, could be sufficient. If
multiple polyps or clusters are found during colonoscopy,
or repeated total colonoscopy is technically difficult, sur-
gical resection is the treatment of choice for these patients.
Subtotal colectomy with an ileorectal anastomosis can
usually be performed due to the relative sparing of the rec-
tum in AFAP. Systematic rectal surveillance is mandatory
after this procedure.
Management of extracolonic adenomas
This is recommended as outlined for FAP, but the risk of
malignancy is much lower.
Prognosis
The goal is pre-symptomatic genetic diagnosis of APC
mutation-carriers that can lead to improved clinical care
and prevent premature mortality from cancer or other FAP
complications. Most patients with clinical FAP can be
identified and have their diagnosis confirmed by genetic
testing. Individuals with FAP carry a 100% risk of colorec-
tal cancer that is reduced almost absolutely when patients
enter a screening-treatment program as outlined earlier.
Once proctocolectomy has been performed, the risk of
ampullary and duodenal cancer is significant and requires
lifelong upper gastrointestinal surveillance that has been
shown to save lives of FAP patients. Desmoids need to be
identified early while small and not causing local pertur-
bations. They should be managed as described above.
Duodenal cancer and desmoids are the two main causes
of mortality after total colectomy has removed the risk for
CRC. The sociological, psychological and physiological
issues related to the diagnosis and treatment of FAP need
to be addressed. The colectomy and ensuing change in
bowel habits, frequently lead to dietary changes that can
be unbalanced and lead to vitamin-mineral deficiencies.
Change in number of colorectal polyps in FAP patients receiving placebo or celecoxib (CelebrexR) for 6 months Figure 10
Change in number of colorectal polyps in FAP patients receiving placebo or celecoxib (CelebrexR) for 6 
months. The reduction in polyp burden, versus placebo, was significant (*P = 0.003) with the dosage of 400 mg twice a day 
(data for figure derived from reference [107]).
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Notable is the possibility of vitamin B12 deficiency due to
rapid intestinal transit, ileal resection and ascending bac-
terial overgrowth. All these problems require systematic
follow-up and supportive care.
Unresolved questions
There are two major issues that need to be addressed.
Firstly, there is a significant minority of patients with clin-
ical FAP that don't have their genetic mutation identified
even with the more sophisticated genetic testing. This
issue means that first-degree relatives cannot be screened
genetically and will require life-time repeated clinical
evaluation to exclude being a carrier of the disorder. Sec-
ondly, there is some clinical evidence supporting the pos-
sibility of influencing the manifestation of disease by
chemoprevention and lifestyle changes. These issues
require further research and evaluation.
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